Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. Multicenter, Randomized, Double-blind, Placebo-controlled Study

Trial Profile

Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. Multicenter, Randomized, Double-blind, Placebo-controlled Study

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Recombinant epidermal growth factor (Primary)
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
    • 21 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Jan 2017.
    • 23 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top